Does Medicare Advantage Cover Testosterone Cypionate?

How Medicare Advantage Part D Covers Testosterone Cypionate

Medicare Advantage plans with prescription drug coverage (MA-PD) include testosterone cypionate on their Part D formularies when prescribed for FDA-approved indications. The primary approved use is replacement therapy in males with conditions associated with a deficiency or absence of endogenous testosterone, as specified in the FDA-approved prescribing information.

Coverage is not automatic. CMS requires Part D sponsors to maintain formularies that meet certain adequacy standards, but individual carriers retain discretion over tier placement, quantity limits, and utilization management tools like prior authorization [1]. A 2020 analysis published in JAMA Internal Medicine found that prior authorization requirements for testosterone products varied substantially across Part D plans, with denial rates ranging from 8% to over 30% depending on the carrier and region [2].

Generic testosterone cypionate injectable (200 mg/mL) typically lands on Tier 1 or Tier 2. That means monthly copays between $0 and $15 for most enrollees, though high-deductible MA-PD plans may require full cost-sharing until the deductible is met. Brand-name Depo-Testosterone, when stocked, usually sits on Tier 3 with higher cost-sharing.

One counterintuitive reality: the generic cash price averages around $60 per month at retail pharmacies. For enrollees in the Part D coverage gap or those with high-deductible plans, paying cash may cost less than using insurance.

Prior Authorization Requirements for Testosterone Cypionate

Prior authorization is the most common barrier Medicare Advantage enrollees face when filling a testosterone cypionate prescription. The typical PA criteria across major carriers follow a predictable pattern.

Plans generally require documentation of two separate morning serum total testosterone levels below 300 ng/dL, drawn between 7:00 AM and 10:00 AM. This threshold aligns with the Endocrine Society's 2018 clinical practice guideline, which recommends diagnosing hypogonadism only when testosterone is "unequivocally and consistently low" on at least two occasions [3]. Some carriers accept a single level below 250 ng/dL.

The prescribing physician must also document signs or symptoms consistent with testosterone deficiency: decreased libido, erectile dysfunction, fatigue, loss of muscle mass, or depressed mood. Lab values alone rarely satisfy PA requirements. Plans want clinical correlation.

Additional documentation that strengthens a PA request includes:

• LH and FSH levels to distinguish primary from secondary hypogonadism
• Prolactin level to rule out pituitary adenoma
• CBC with hematocrit as a baseline safety measure (testosterone raises hematocrit)
• PSA in men over 40, per American Urological Association screening recommendations

PA approvals typically last 12 months. Reauthorization may require updated labs showing testosterone levels within the therapeutic range (400 to 700 ng/dL on trough draws) and a hematocrit below 54%.

Formulary Tier Placement Across Major MA Carriers

Generic testosterone cypionate occupies favorable formulary positions across the largest Medicare Advantage carriers. Tier placement directly determines out-of-pocket cost.

Carriers including UnitedHealthcare, Humana, Aetna, and Cigna generally place generic testosterone cypionate injectable on Tier 1 (preferred generic) or Tier 2 (non-preferred generic). Tier 1 copays range from $0 to $10 per fill. Tier 2 copays range from $5 to $20. These amounts apply during the initial coverage phase.

Brand-name Depo-Testosterone, when available on formulary, sits on Tier 3 (preferred brand) with copays of $30 to $50 or coinsurance of 20% to 33%. Many plans have removed the brand entirely from formulary since multiple generic alternatives exist.

Formulary placement changes annually. CMS requires carriers to publish updated formularies by September 15 for the following plan year. Enrollees can search their specific plan's drug list on Medicare.gov's Plan Finder tool or call the carrier directly. The Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled studies published in The New England Journal of Medicine, demonstrated that testosterone treatment in men 65 and older with low testosterone improved sexual function, physical function, and vitality [4]. These findings have supported continued Part D coverage of testosterone replacement for age-related hypogonadism.

Step Therapy: When Plans Require Trying Another Formulation First

Some Medicare Advantage plans impose step therapy protocols that require a trial of topical testosterone before approving injectable testosterone cypionate. This means the plan wants evidence that the enrollee tried and failed (or cannot tolerate) a testosterone gel or patch before it will cover the injectable.

Step therapy makes clinical sense in some cases. Topical formulations offer steady-state testosterone levels and avoid the peak-trough cycling associated with intramuscular injections given every one to two weeks [5]. The Endocrine Society guideline does not preferentially recommend one formulation over another, stating that the choice should be "a joint decision by the patient and clinician" [3].

But step therapy creates real problems for certain patients. Men who live with young children or female partners face transference risk with topical testosterone, a concern the FDA addressed with a boxed warning on all topical testosterone products [6]. Patients with dermatologic conditions affecting application sites, those who swim or exercise heavily (which compromises gel absorption), or individuals with documented skin reactions to topical vehicles may qualify for step therapy exceptions.

To request a step therapy exception, the prescriber submits documentation showing:

• Medical necessity for the injectable route
• Clinical rationale for bypassing topical formulation
• Any adverse effects experienced with prior topical testosterone use

Plans must respond to exception requests within 72 hours for standard requests and 24 hours for expedited requests under CMS rules.

Why Medicare Part D Does Not Cover Testosterone for Weight Loss

Federal CMS rules explicitly exclude weight-loss drugs from Part D coverage, with narrow exceptions. Testosterone cypionate prescribed solely for weight management or body composition improvement will be denied.

This exclusion applies even though testosterone replacement produces measurable changes in body composition. A meta-analysis of 37 randomized controlled trials (N = 3,053) published in Clinical Endocrinology found that testosterone therapy in hypogonadal men reduced fat mass by an average of 1.6 kg and increased lean mass by 1.6 kg over study periods ranging from 3 to 36 months [7]. These body composition shifts, while real, do not constitute an FDA-approved weight-loss indication.

The March 2024 CMS policy update that expanded Part D coverage to include certain GLP-1 receptor agonists (specifically semaglutide for cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease) does not extend to testosterone products [8]. Testosterone cypionate's FDA label restricts its approved use to replacement therapy for hypogonadism. Off-label prescribing for weight loss will not receive Part D coverage.

Physicians who believe testosterone replacement is medically necessary for a patient with concurrent hypogonadism and obesity should document the hypogonadism diagnosis as the primary indication. The weight-loss benefit, if it occurs, is incidental to treating the underlying endocrine disorder.

How to Appeal a Medicare Advantage Denial of Testosterone Cypionate

Medicare Advantage denials for testosterone cypionate follow a structured, five-level appeals process defined by CMS regulations. Knowing each level and its timeline gives enrollees the best chance of overturning a denial.

Level 1: Plan Reconsideration. Filed with the Medicare Advantage carrier within 60 days of the coverage determination. The plan must decide within 30 days (standard) or 72 hours (expedited). Include all supporting lab work, clinical notes, and a letter of medical necessity from the prescribing physician. According to CMS data from 2023, approximately 75% of Part D coverage determination appeals were decided in the enrollee's favor at this level [9].

Level 2: Independent Review Entity (IRE). If the plan upholds its denial, the case automatically forwards to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS reviews the case independently and issues a decision within 7 days (standard) or 72 hours (expedited). The enrollee can submit additional documentation at this stage.

Level 3: Office of Medicare Hearings and Appeals (OMHA). If the IRE upholds the denial and the amount in controversy meets the threshold ($180 in 2025), the enrollee can request an Administrative Law Judge hearing. Processing times average 90 days.

Level 4: Medicare Appeals Council. Reviews ALJ decisions upon request.

Level 5: Federal District Court. Available if the amount in controversy exceeds $1,760 (2025 threshold).

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and lead author of the Endocrine Society's testosterone guideline, has noted: "The majority of testosterone denials I see in clinical practice stem from incomplete documentation rather than inappropriate prescribing. Two morning testosterone levels, symptoms, and a clear ICD-10 code resolve most appeals at the first level" [3].

For the strongest appeal, include a peer-reviewed citation supporting the clinical indication. The T-Trials, published across multiple NEJM papers, remain the most frequently cited evidence base for testosterone replacement in older men with low levels [4].

Manufacturer Savings Cards and Medicare: What the Law Says

Federal anti-kickback statutes prohibit Medicare beneficiaries from using manufacturer copay cards, discount coupons, or savings programs to reduce out-of-pocket costs for Part D drugs. This is not a carrier-specific policy. It is federal law under the OIG Special Advisory Bulletin on Patient Assistance Programs [10].

This prohibition applies to all Medicare enrollees, including those in Medicare Advantage plans with Part D coverage. A testosterone cypionate manufacturer coupon that works for commercially insured patients cannot legally be applied at the pharmacy counter for a Medicare beneficiary.

Alternatives do exist. Patient assistance programs (PAPs) operated by manufacturers may provide free medication to Medicare beneficiaries who meet income thresholds. The Extra Help / Low-Income Subsidy (LIS) program reduces Part D cost-sharing for enrollees with limited income and resources. State Pharmaceutical Assistance Programs (SPAPs) in some states supplement Part D coverage.

Given that generic testosterone cypionate costs approximately $60 per month at cash price through discount pharmacy programs, some Medicare enrollees find that bypassing Part D entirely and paying cash results in lower total cost than their plan copay plus any deductible obligations.

Comparing Injectable vs. Other Testosterone Formulations on Medicare Formularies

Medicare Advantage formularies typically cover multiple testosterone formulations, each with different tier placements and utilization management requirements.

Injectable testosterone cypionate (generic) occupies the most favorable cost position. Testosterone enanthate, another injectable ester, carries similar tier placement and pricing. The two are clinically interchangeable for most patients, with cypionate having a slightly longer half-life (approximately 8 days vs. 4.5 days for enanthate) [11].

Topical testosterone gels (1% and 1.62%) sit on Tier 2 or Tier 3 depending on the specific product and carrier. AndroGel, Testim, and Vogelxo are common brand names; authorized generics are increasingly available. Monthly costs under Part D range from $15 to $75 after copay.

Testosterone patches (Androderm) generally occupy Tier 3 with copays of $30 to $50. Nasal testosterone (Natesto) and oral testosterone undecanoate (Jatenzo) sit on Tier 3 or are excluded from formulary entirely due to higher acquisition costs.

Subcutaneous testosterone pellets (Testopel) require a separate procedure and are covered under Part B (medical benefit) rather than Part D. The insertion procedure carries its own CPT code (11980) and reimbursement schedule.

For cost-conscious Medicare enrollees, generic injectable testosterone cypionate remains the least expensive option, both under Part D coverage and at cash-pay prices. The American Association of Clinical Endocrinology (AACE) 2024 consensus statement on male hypogonadism acknowledges that injectable testosterone esters "remain the most cost-effective formulation for long-term testosterone replacement" [12].

Monitoring Requirements That Affect Ongoing Coverage

Medicare Advantage plans that approve testosterone cypionate typically require periodic monitoring labs for continued coverage. These monitoring visits are covered under Part B (medical benefit), not Part D.

Standard monitoring protocols, consistent with the Endocrine Society guideline, include serum testosterone levels at 3 months, then every 6 to 12 months, drawn as trough values (immediately before the next scheduled injection). Target trough levels of 400 to 700 ng/dL confirm adequate dosing [3].

Hematocrit monitoring is mandatory. Testosterone stimulates erythropoiesis, and hematocrit values exceeding 54% require dose reduction or temporary discontinuation. The T-Trials found that testosterone treatment increased hematocrit by a mean of 2.5 percentage points compared to placebo over 12 months, with 4.2% of treated men exceeding the 54% threshold vs. 0.3% on placebo [4].

PSA testing in men over 40 should occur at baseline, 3 to 6 months, then annually. A PSA increase exceeding 1.4 ng/mL within any 12-month period warrants urological evaluation, per AUA/Endocrine Society joint recommendations [13].

Lipid panels and hepatic function tests are recommended at baseline and annually. Bone mineral density testing via DXA may be appropriate in men with documented osteoporosis or fragility fractures who initiated testosterone for hypogonadism-related bone loss [14].

Failure to maintain monitoring labs can result in PA denial at reauthorization. Clinicians should document all monitoring encounters in the medical record and reference them explicitly when submitting reauthorization requests. A hematocrit drawn within 90 days of the reauthorization date and a trough testosterone level within the target range (400 to 700 ng/dL) are the two most consistently required data points across carriers.